SmithKline LYMErix Dosing Studies For Earlier Efficacy Urged By FDA Cmte.
Executive Summary
SmithKline Beecham should conduct a dosing study of its LYMErix vaccine to see if immunity to Lyme disease can be established more quickly than with the proposed three-dose/one-year schedule, FDA's Vaccines & Related Biological Products Advisory Committee agreed at a meeting May 26.
You may also be interested in...
LYMErix Product Liability Suit Seeks Testing For OspA Sensitivity
A product liability lawsuit is arguing that SmithKline Beecham's LYMErix vaccine should be used only in patients that have been tested for sensitivity to the outer surface protein A Lyme disease vaccine.
LYMErix Product Liability Suit Seeks Testing For OspA Sensitivity
A product liability lawsuit is arguing that SmithKline Beecham's LYMErix vaccine should be used only in patients that have been tested for sensitivity to the outer surface protein A Lyme disease vaccine.
Lymerix Two-Month Dose Expected By Mid-2000, Pediatric Data By Year-End
SmithKline Beecham's Lymerix two-month accelerated dosing regimen could receive FDA approval in the first half of 2000, Jean-Pierre Garnier, PhD, said Sept. 16 at the Bear Stearns health care conference in New York City.